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Summary Background We attempted to determine the maximum tolerated dose and toxicity of etoposide
(VP-16) when administered in combination with carboplatin (CBDCA) (300 mg m-2) and administered via the
intraperitoneal (IP) route.
Methods and Materials A total of 26 patients were treated on this trial. CBDCA was administered at a
fixed dose of 300 mg m-2) while VP-16 was started at a dose of 200 mg m2 and escalated at 50 mg m-2
increments. Both agents were mixed together in 2 litres of 5% Dextrose and administered as quickly as
possible into the peritoneal cavity. Pharmacokinetic studies were performed at the maximum tolerated dose
(MTD).
Results The MTD for this regimen was CBDCA 300 mg m-2 and VP-16 350 mg m-2. Patients > 70 years
of age or who had received more than six cycles of previous chemotherapy, tolerated this regimen poorly. The
MTD for this group of patients was CBDCA 200 mg m-2 and VP-16 50 mg m-2. Neutropenia was the dose
limiting toxicity for both groups. The mean peritoneal/plasma peak ratio was 18.3 for CBDCA and 12.7 for
VP-16. The pharmacologic advantage (peritoneal/plasma AUC ratio) was 14.9 for CBDCA and 8.8 for VP-16.
Although measurable disease was not a requirement for entrance into this study a response rate of 27% was
noted in 15 patients with evaluable disease who had ovarian cancer.
Conclusions A pharmacologic advantage exists for both CBDCA and VP-16 when administered together
via the IP route.
We have recently completed phase I and II trials of the
combination of high dose cisplatin and etoposide admini-
stered concurrently via the intraperitoneal route (Howell et
al., 1990; Kirmani et al., 1988; Zimm et al., 1987). This
combination demonstrated substantial activity as both a sal-
vage regimen as well as initial therapy (Howell et al., 1990;
Kirmani et al., 1988). This information has been used to
design a phase III prospective randomised trial comparing
standard intravenous cisplatin and cyclophosphamide with
high dose cisplatin and etoposide administered intraperi-
toneally that is currently ongoing at the UCSD Cancer
Center.
Carboplatin, a cisplatin analogue, has recently been
approved for use for the treatment of ovarian cancer by the
Food and Drug Administration. It has demonstrated sub-
stantially less nephrotoxicity, neurotoxicity and ototoxicity
while it appears to be as effective as cisplatin for the treat-
ment of ovarian cancer when used in appropriate doses
(Alberts et al., 1985; Anderson et al., 1988; ten Bokkel
Huinink et al., 1988). Additionally two phase I and one
phase II trials of the intraperitoneal administration of car-
boplatin have been completed (DeGregorio et al., 1986;
Elferink et al., 1988; Speyer et al., 1990). In patients with
creatinine clearances of greater than 60ml per minute the
maximum tolerated dose was in excess of 400 mg m-2 in both
studies. The dose limiting toxicity was myelosuppression with
little evidence of chemical peritonitis. Pharmacokinetic
studies have demonstrated a peritoneal to plasma AUC ratio
of approximately 14-fold. Clinical responses were observed in
all of the studies.
Based on the activity of the intraperitoneal cisplatin/etopo-
side combination and the difference in the pattern of toxi-
cities of carboplatin, we sought to determine whether or not
carboplatin could be substituted for cisplatin in this com-
bination. The purposes of this trial were to: (1) determine the
maximum tolerated dose of etoposide that can be administer-
ed via the IP route concurrently with a fixed dose of carbo-
platin (300 mg m-2), (2) determine the pattern of toxicity
produced by this drug combination given by the IP route, (3)
determine the intraperitoneal pharmacokinetics of each agent
at the recommended phase II dose level.
Material and methods
Patient eligibility and characteristics
Patients were eligible for participation in this trial if they
were 18 years of age or older and had a histologically proven
diagnosis of cancer that was refractory to or relapsed after
conventional modes of therapy or for which no effective
chemotherapy exists. All patients were fully ambulatory and
had a life expectancy of at least eight weeks. Patients had to
have recovered from the toxic effects of prior therapy and
have normal renal (creatinine < 1.5 mg dl-') and hepatic
function (bilirubin <1.5 mg%, SGOT less than three times
the upper limit of normal). Hematologic parameters required
a granulocyte count greater than 1,500 mm-3 and platelet
count greater than 100,000 mm-3. Written informed consent
was obtained prior to entry on the study. The common
toxicity scale was used to grade toxicity.
Twenty-six patients were entered. All were evaluable for
toxicity. While 21 are evaluable for response on the basis of
having either a lesion measurable on physical exam or radio-
graphic study or at subsequent laparotomy. Five patients did
not have measurable disease upon entry onto the study. A
total of 91 evaluable courses were administered to these
patients. Twenty-one patients were female and five were
male. The median age was 59 with a range from 26 to 83.
ECOG performance status ranged from 0 to 2. Eighteen
patients had ovarian cancer, three had gastric, two had
colon, and one each had fallopian tube, pancreas and sar-
coma. Nineteen patients had received prior chemotherapy,
and seven had received prior radiation therapy. Seventeen
patients had received prior cisplatin containing regimens, and
eight had received prior intraperitoneal chemotherapy. Six
patients (two gastric carcinoma, one pancreatic carcinoma,
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two colon carcinoma, one sarcoma) had no prior form of
therapy other than surgery.
Study design and treatment plan
Patients were to receive a fixed dose of carboplatin (300 mg
m_2) and increasing doses of etoposide starting at 100 mg
m-2 and escalating at increments of 50 mg m-2 until a max-
imum tolerated dose was identified. However, there were two
grade 4 hematologic toxicities among the first three patients
prompting dose reductions. Re-evaluation after nine patients
were entered revealed that the patients who encountered
grade 4 hematologic toxicity were elderly (age greater than
70) or had received more than six cycles of previous chemo-
therapy. Thereafter, patients were stratified into high risk
(age greater than 70 or greater than six cycles of chemo-
therapy) and low risk groups. High risk patients were started
at a dose of 200 mgm-2 of carboplatin and 50mgm2 of
etoposide while low risk patients were entered according to
the original dose escalation scheme. A minimum of three
patients were treated at each dose level of etoposide prior to
escalation. Dose escalations were carried out both within and
between patients until dose limiting toxicity was reached. All
patients were eligible for dose escalation providing they had
recovered from their previous cycle of therapy and other
requirements for escalation satisfied. This study design allows
for quick dose escalation but it is difficult to evaluate the
effect of cumulative toxicity.
Cycles of therapy were repeated at 4 week intervals follow-
ing recovery from toxicity produced by the prior cycle. The
maximum tolerated dose was defined as the occurrence of
grade 4 hematologic toxicity in more than one of six patients
treated at a particular dose level. Patients who experienced
grade 4 hematologic toxicity were treated at the next lowest
etoposide dose level on subsequent cycles of chemo-
therapy.
Patients were hospitalised for the initial course of therapy.
Those patients who tolerated therapy well (minimum nausea
and vomiting) were eligible for treatment as an outpatient.
The appropriate dose of carboplatin and etoposide was mix-
ed together in two litres of 5% dextrose in water and admin-
istered as rapidly as possible (45-90 min) into the peritoneal
cavity. HPLC analysis demonstrated that the two drugs were
chemically compatible and failed to react with each other at
these concentrations (data not shown). A totally implanted
peritoneal access system (Port-a-Cath, Pharmacia nuTech,
Piscataway, New Jersey) was used in this study. Fluid was
not removed from the peritoneal cavity. No systemic hydra-
tion was used routinely unless the patient encountered signi-
ficant problems with nausea and vomiting. The anti-emetic
regimen included the use of lorazepam, metaclopramide and
diphenhydramine.
Sample collections andpharmacokinetics
Blood samples were obtained prior to therapy and then at 14
additional time points over an 8 h interval from the start of
chemotherapy. In addition, blood samples were collected at
8, 12, and 24 h. The peritoneal fluid samples were collected at
the instant the IP infusion ended (ranging from 45-90 min)
and every hour for 8 h after the start of chemotherapy.
Additional samples were collected at 24 h.
The blood and peritoneal fluid samples were drawn into
chilled heparinised tubes and then immediately centrifuged at
1000 g for Omin at 4°C to remove the formed elements. A
portion of the peritoneal and plasma fluid samples was
immediately ultrafiltered by centrifugation through CF25A
filter cones (Amicon Corp., Lexington, Massachusetts). The
unfiltered plasma and peritoneal fluid samples, as well as
their respective ultrafiltered samples, were frozen at - 70°C
for later carboplatin and etoposide analysis.
Ultrafilterable carboplatin concentrations were measured
in the form of elemental platinum by graphite furnace atomic
absorption spectroscopy using a Perkin-Elmer 373 atomic
absorption spectrophotometer equipped with an HGA-2200
graphite furnace, with a lamp current of 15 mA and monitor-
ing of the 265.9 nm line. Injection of volumes of 2 to 20pl of
thawed ultrafiltrate were analysed using the following temp-
erature program: dry at 100°C for 50 s, ramp to 1300°C over
10 s, char at 1300°C for 15 s, and atomise at 2350°C for 7 s.
The standard lines for both peritoneal fluid and plasma
samples were constructed by dissolving cisplatin (Bristol-
Myers Company, Syracuse, New York) in 0.9% saline.
Total etoposide concentrations were determined by using
reverse phase high performance liquid chromatography as
previously described (Strife et al., 1986; Zimm et al., 1987).
Tenopside (VM-26) was used as the internal standard. Stan-
dard curves were constructed in either saline, for analysis of
peritoneal fluid, or the patient's own plasma, obtained before
the start of chemotherapy, for the analysis of plasma levels.
The chromatographic apparatus included a Waters 6000A
solvent pump (Waters Associated, Inc., Norford, Massachu-
setts), a Waters 715 ULTRA automatic sample injector, and
a Waters 440 ultraviolet absorbance detector. Chromato-
graphic separation was done with a Waters 10 x 8 cm radial-
pak C18 cartridge (10fIM) particle size inserted inside a
Waters RCM 8 x 10 compression module. The Maxima 820
software (Millipore Corporation, Millford, Massachusetts) in
an IBM compatible Hewlett Packard Vectra personal com-
puter was used to operate each run and create the corre-
sponding chromatograms.
In order to model the pharmacokinetic data, account must
be taken of the fact that drug instillation did not occur
instantaneously but required 45-90 min. Thus one and two
compartment models that consider only the decay are not
entirely appropriate. In order to model the situation more
accurately coupled differential equations were set up to
model the elimination and exchange of carboplatin or etopo-
side (drug) between the peritoneal and plasma compartments
by a method previously described (Goel et al., 1989;
1992).
The pharmacokinetics of carboplatin during infusion
(O <t <T) can be depicted by the system diagram (see
Figure 1) where VI and V2 are the apparent volumes of the
respective compartments, k12 and Ke, are the elimination rate
constants and Q is the flow rate into the peritoneal cavity.
Under the first order kinetics, differential equations describ-
ing the rates at which the concentrations in each compart-
ment CI(t) (peritoneal cavity) and C2(t) (plasma) change with
time are:
Peritoneal fluid: dCi k12 Cl (t)+ Q dt 12 VI
Plasma: dC2 _
dt
with initial conditions CI(O) = C2(0) = 0. The solutions
are:
C, (t) = Q [ 1-e1kl2t ] (1)
V2kekte1 [ 1-k,- e1kk2kt e-ket ] (2)
After infusion (t , T), the system diagram is as shown in
Figure 1, and the differential equations are:
dC
dt =-k12 Cl (t)
dC2 t V2 k12 Cl (t)-ke C2 (t)
The solutions are:
C1 (t) = Ale k12' (3)
C2 (t) = V1kl2A e-k12t + A2e-ket V2 (ice-k12) 4
V' k12 Cl(t) ke C2 (t) V2
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Figure 1 Drug is administered into the peritoneal cavity at rate
Q, distributes in apparent volume VI and is eliminated at rate
constant K,2. Drug that reaches the plasma is distributed in
apparent volume V2 and eliminated at rate constant K¢.
Where A' and A2 are intercepts determined for each of the
compartments determined by extrapolation of the elimination
phase of the curve to t = 0. Continuity requirements at t = T
allow us to determine Al and A2. Thus equations (1) and
(3) are combined - and similarly with equations (2) and (4) -
to give:
C, (t) = e [ e2(t-T) - e-kl2t (5)
C2 (t) V2ke Lk - k, (e kI2(t-T) - ek12t) -
kk2 (eke(t-T)- eket)] (6) k, - k12
where (r)+= max (O,T), for all t> 0.
An iterative one-dimensional 'grid search' for k,2, coupled
with standard linear regression to estimate Q/V,, was used to
fit Equation (5) to the peritoneal carboplatin measurements
of each patient: least squares estimates of Q/V, and k12 were
thus obtained. The estimate of k,2 was then inserted in
equation (6) and held fixed, and by the same technique least
squares estimates of Q/V2 and ke were obtained from the
patient's plasma CBDCA measurements. The major pharma-
cokinetic parameters were then calculated.
The areas under the fitted concentration (AUCs) vs time
curves were calculated by the integration of the correspon-
ding peritoneal and plasma equations out to t = mo. The
results were AUC = (Q/Vlkl2)T for the peritoneum and
AUC = (Q/V2ke)T for the plasma. The volume of distribution
is then given by dose/(kl2 *AUC) for the peritoneum and
dose/(ke AUC) for the plasma. Clearance is given by dose/
AUC, and half-life is given by In 2/(elimination rate con-
stant). The peritoneal mean residence time is given by (1/
k,2) + (T/2). Calculations were carried out on the data for
each patient separately.
Results
Toxicity
Ninety-two courses were administered to 26 patients. The
major dose limiting toxicity encountered in this study was
myelosuppression. Tables I and II present the hematologic
toxicity as a function of dose for the high and low risk
groups respectively. Grade 4 toxicity was seen in both
neutrophil and platelet lineages and both qualified as dose
limiting toxicity for both low and high risk groups. The
recommended phase II dose is carboplatin 300mgm-2 and
etoposide 100 mg m-2 for high risk patients and carboplatin
300mgm-2 and etoposide 350mgm-2 for low risk patients.
Only two of the courses were associated with neutropenic
fever. Offending organisms were not identified and the
patients recovered on appropriate antibiotic coverage. One
patient had a culture documented infectious peritonitis that
was successfully treated without having to remove the port-
A-cath. One patient had a port infection that required
removal of the port. There were no episodes of chemical
peritonitis and no treatment related deaths.
Unexpectedly, two patients experienced profound nephro-
toxicity. Patient 15 experienced a marked rise in her serum
creatinine to 8.2 mg dl-' documented on day 7 after her
fourth cycle while patient 20 experienced a rise in her
creatinine to 9.1 mgdl-' on day 5 after her fifth cycle of
therapy. In retrospect, it was noted that both patients had
received a significant amount of cisplatin with prior treat-
ment. Patient 15 had a total dose of cisplatin equal to
1800mgm-2 while patient 20 had a total dose of cisplatin
equal to 1500mgm-2. The majority of the cisplatin admin-
istered in both patients was given in conjunction with sodium
thiosulfate as part of another intraperitoneal pharmaco-
kinetic study. The creatinine clearance prior to treatment was
unavailable for patient 15 but was 68 ml per minute for
patient 20. Both patients underwent renal biopsy which re-
vealed diffuse interstitial nephritis. Subsequently, prednisone
was initiated with improvement in the serum creatinine, how-
ever, it never normalised in either patient necessitating their
removal from study. Unfortunately, both patients had dem-
onstrated an encouraging partial response up to the point of
toxicity.
One patient experienced progression of neuropathy that
had previously developed while on cisplatin based therapy. It
was unclear whether this was secondary to the carboplatin or
was part of a natural progression of cisplatin neurotox-
icity.
Nausea and vomiting was mild and routinely controlled
with standard antiemetics. No hepatotoxicity was observ-
ed.
Pharmacokinetics
The pharmacokinetics of ultrafilterable carboplatin at a dose
of 300 mg m-2 and total etoposide at a dose of 350 mg m 2
were each determined for six separate courses of therapy in
six different low risk patients. Each patient had a creatinine
clearance that was greater than 60 ml min-'. Figure 2 shows
the plasma and peritoneal concentrations of carboplatin,
measured as elemental ultrafilterable platinum; Figure 3
shows the concentrations of total etoposide. The pharmaco-
kinetic parameters are summarised in Tables III and IV.
As shown in Figure 2, peritoneal concentrations of carbo-
platin were markedly higher than plasma concentrations. The
total AUC of carboplatin in the peritoneal and plasma com-
partments were 3,673 ± 4,202 (SD) ,LM-h and 247 +
194 gM h respectively and the mean peritoneal:plasma AUC
ratio (± standard deviation) was 14.5 ± 6.9.
As shown in Figure 3 peritoneal concentrations of total
etoposide were also markedly higher than plasma concentra-
tions. The total AUC in the peritoneal and plasma compart-
ments were 2,752 ±2,109fg h ml-' and 314± 123 ig h ml'
respectively. The mean AUC ratio was 9.6 ± 9.5.
Response
Although this trial was designed as a phase I pharmaco-
kinetic study and measurable disease was not required for
entry, responses were observed. Clinically meaningful res-
ponses occurred only in patients with ovarian cancer. Among
the 18 patients with ovarian cancer entered onto this study 3
did not have measurable disease and therefore are evaluable
only for toxicity. Of the 15 patients evaluable for response 2
demonstrated a complete respons (one pathologic, one clini-
cal) lasting 8+ and 18 months respectively. Two patients had
a partial response documented by CT scan and normalisation
of their CA-125. Thus, the overall response rate in ovarian
cancer was 27%. Two additional patients demonstrated
disease stabilisation on CT scan lasting 4 and 6 months with
normalisation of their CA-125. Two patients, without
measurable disease, who had a positive peritoneal cytology
and an elevated CA-125 at the start of therapy demonstrated
complete normalisation of both parameters lasting 14 and 4+786 E.F. McCLAY et al.
Table I Hematologic toxicity high risk patientsa
Dose level (mgm-2) Granulocytes Toxicity grade Platelets
Carboplatin Etoposide No. patients No. courses 0 1 2 3 4 0 1 2 3 4
100 50 1 1 1 0 0 0 0 1 0 0 0 0
200 50 10 16 5 1 6 4 0 8 2 3 2 1
300 50 9 18 0 5 7 2 4 3 2 5 4 4
300 100 4 4 0 2 0 0 2 1 0 0 2 1
300 150 1 1 0 0 0 1 0 0 0 0 1 0
300 200 1 1 0 1 0 0 0 0 1 0 0 0
Total 41
aHigh risk - more than six prior cycles of chemotherapy or age greater than 70.
Table II Hematologic toxicity low risk patientsa
Dose level (mgm r2) Granulocytes Toxicity grade Platelets
Carboplatin Etoposide No. patients No. courses 0 1 2 3 4 0 1 2 3 4
300 50 2 2 1 1 0 0 0 2 0 0 0 0
300 75 2 4 0 0 3 1 0 4 0 0 0 0
300 100 3 3 2 1 0 0 0 3 0 0 0 0
300 150 3 8 0 1 2 6 0 4 1 3 1 0
300 200 4 7 1 0 4 1 1 6 0 0 0 1
300 250 5 5 1 1 0 3 0 4 1 0 0 0
300 300 5 5 1 0 3 1 0 5 0 0 0 0
300 350 7 12 1 3 4 2 2 8 1 1 2 0
300 400 5 5 0 1 1 1 2 3 0 0 2 0
Total 51
aLow risk - less than six prior cycles of chemotherapy and age less than 70.
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Table III Carboplatin pharmacokinetic parameters (300 mgm-2)
Peritoneal Plasma
(mean ± s.d.) (mean ± s.d.)
AUC (0-*oo) 3673 4202 .M h 247 194jAm h
T,/2 4.2+5.1 h 0.8+0.5h
VDa 2.4 0.8 litres 9.6 9.1 litres
Clearancea 0.7 0.5 litres h-' 8.8 5.5 litres h-'
Mean residence time 7.1 ± 7.2 h
Peak Conc. 479 155Mm 28 8gM
Plateau Conc. 2713 3517 ,AM 172 174Mm
Mean Peritoneal/Plasma AUC ratio = 14.5 ± 6.9
Mean Peritoneal/Plasma Peak = 18.3 ± 7.6
Concentration Ratio
aThese parameters have been calculated with the assumption that
all intraperitoneal carboplatin is absorbed into the systemic
circulation without undergoing metabolism in transit.
Figure 2 Peritoneal (open circles) and plasma (closed circles)
concentrations of elemental ultrafilterable platinum after i.p.
administration of 300 mg m 2 carboplatin. Data points represent
the mean platinum concentrations determined from six courses.
Error bars represent SD at each time point.
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Figure 3 Peritoneal (open circles) and plasma (closed circles)
concentrations of total etoposide after i.p. administration of
etoposide 350 mg m-2. Data points represent the mean total
etoposide concentration determined from six courses. Error bars
represent SD of etoposide concentrations at each time point.
Table IV Etoposide pharmacokinetic parameters (350mgm2)
Total Drug
Peritoneal Plasma
(mean ± s.d.) (mean ± s.d.)
AUC (0+Xo) 2752 2109 tLg-h ml 314 123pg h mlh
T1/2 5.3 3.5 h 1.3 0.9 h
VDa 1.7 0.4 litres 3.9 3.3 litres
Clearancea 0.3 ± 0.2 litres h-' 1.9 ± 0.6 litres h-
Mean residence time 8.3 ± 4.9 h -
Peak Concentration 302 ± 67gLg ml-' 27 ± 9fig ml-'
Plateau Conc. 2628 ± 2126,Lg mll 293 ± 159,Ag mll
Mean Peritoneal/Plasma AUC ratio = 9.6 ± 9.5
Mean Peritoneal/Plasma Peak = 12.7 ± 8.2
Concentration Ratio
aThese parameters have been calculated with the assumption that
all intraperitoneal carboplatin is absorbed into the systemic
circulation without undergoing metabolism in transit.
months. Patients with ovarian cancer who responded to this
18 24 regimen had both failed (two) and relapsed from (two) pri-
mary cisplatin based therapy.
Discussion
Dose intensity appears to be an important determinant of
survival in patients with ovarian carcinoma. Intraperitoneal
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administration of cisplatin and etoposide results in a peri-
toneal exposure to cisplatin which is 12- to 15-fold greater,
and for free etoposide 65-fold greater, than for the plasma.
We have previously demonstrated the activity of this two
drug combination administered intraperitoneally for the
treatment of newly diagnosed ovarian carcinoma (Howell et
al., 1990). A further increase in dose intensity could be
accomplished by increasing cisplatin dose, but the cisplatin
dose cannot be increased above 270 mg m-2 even when thio-
sulfate is used, before encountering dose-limiting non-hema-
tologic toxicities (Pfeifle et al., 1985).
In contrast, carboplatin has been given successfully at
doses up to 1600 mgm-2 without substantial toxicity other
than bone marrow suppression (Gore et al., 1987; Meyers et
al., 1989; Shea et al., 1989). As a first step in the develop-
ment of a combination that would permit further dose esca-
lation of the platinum compound, we have conducted this
phase I/pharmacokinetic trial to define the maximum toler-
ated dose and toxicity ofcarboplatin given concurrently with
etoposide by the intraperitoneal route.
Early on we encountered substantial myelosuppression at
relatively low drug doses. Careful evaluation of the data,
however, indicated that myelosuppression was occurring in
patients who had previously received multiple chemothera-
peutic regimens or were older than 70 years of age. Colombo
et al. (1989) have recently reported similar problems with
severe hematologic toxicity in patients treated with carbo-
platin who had previously been treated with other chemo-
therapeutic agents. We thereafter stratified the patients into
high risk (age greater than 70, greater than six cycles of
chemotherapy) or low risk (no high risk factors) groups.
Prior to recognising this, however, four patients were de-
escalated to doses lower than the original planned starting
dose. This had the effect of skewing the data for hematologic
toxicity in patients treated at lower doses as several low risk
patients were treated at lower doses and escalated as
tolerated.
The maximum tolerated dose for high risk patients was
200 mg m-2 of carboplatin and 50 mg m-2 of etoposide while
for low risk patients the maximum tolerated dose was
300 mg m-2 of carboplatin and 350 mg m-2 of etoposide.
Myelosuppression was the dose limiting toxicity for both
groups.
The dose achieved in low risk patients compares
favourably with that achieved in several phase I-II studies
using this combination administered systemically. Bishop et
al. (1987) evaluated the efficacy and toxicity of carboplatin
(100 mg m-2) and etoposide (120 mgm-2) administered int-
ravenously daily for 3 days in 94 patients with previously
untreated small cell lung cancer. According to the Common
Toxicity Grading Scale, Grade 3 or 4 neutropenia and
thrombocytopenia occurred in 63% and 20% of patients
respectively. Two patients died of neutropenic septic
shock.
Smith et al. (1987) evaluated this combination using a
slightly different dose and schedule in a similar patient
population. Carboplatin was given at a dose of 300 mg m-2
intravenously on day 1 while etoposide was administered at a
dose of 100 mg m-2 on days 1 through 3. Common Toxicity
Scale grade 3 or 4 neutropenia and thrombocytopenia occur-
red in 43% and 10% of patients respectively. One patient
died of neutropenic septic shock.
In the present study, two of five patients treated with
carboplatin at a dose of 300 mg m-2 and etoposide at a dose
of 400 mg m-2 experienced grade 4 hematologic toxicity.
Thus carboplatin 300 mg m-2 and etoposide 350 mg m-2 was
identified as the maximum tolerated dose.
As expected, the pharmacokinetic studies confirmed the
significant pharmacologic advantage that can be achieved
when these agents are administered via the intraperitoneal
route. The peak concentration (mean ± SD) of carboplatin
in the peritoneal cavity averaged 18.3 ± 7.6 (SD) fold higher
than that in the plasma and the peritoneal/plasma AUC ratio
averaged 14.5 ± 6.9. Also of importance is the fact that
cytotoxic peritoneal concentrations were maintained for
longer than 24 h; thus the practice of draining the abdomen
after a 4 to 6 h dwell could result in a significant reduction in
peritoneal drug exposure.
Elferink et al. (1988) studied the pharmacokinetics of int-
raperitoneal carboplatin administered as a single agent at a
dose of 300 mg m-2. The AUC ratio of 11.0 ± 8.0 that they
determined was similar to our ratio of 14.5 ± 6.9. Strict
comparison of other pharmacokinetic parameters could not
be made as they used a two compartment model analysis. In
Elferink's analysis, within each body cavity, a pharmacologic
2-compartment model is used while in our study, within each
body cavity, a pharmacologic one-compartment model is
used.
Similarly, DeGregorio et al. (1986) found an AUC ratio of
18.2 ± 10.2 for single agent carboplatin at a dose of
200 mg m-2. Their calculated values of peritoneal mean
residence time (4.70 ± 1.6 h) and peritoneal clearance
(0.66 ± 0.35 L h-') were not statistically different from our
own (grouped t test P> 0.05).
A significant pharmacologic advantage was also demon-
strated for etoposide. The peak concentration in the
peritoneal cavity averaged 12.7 ± 8.2 (SD) fold higher than
that in plasma. The mean peritoneal/plasma AUC ratio for
total drug was 9.6 ± 9.5 (SD).
These values are in contrast to those obtained by O'Dwyer
et al. (1991) who evaluated the pharmacokinetics of
etoposide given intraperitoneally as a single agent. AUC
ratios ranging between 1.4 and 3.26 were obtained using
doses between 100 and 800 mg m-2. These ratios cannot be
strictly compared, however, as the dwell time in their study
was only 4 h and the variances of the AUC ratios were
different in the two studies. The peritoneal half life and
clearance were similar, but there was a significant difference
in the plasma half life and clearance. For reasons that are
not immediately apparent the plasma clearance for etoposide
was higher in our study. Once again significant levels of
VP- 16 were still present at 24 h indicating that peritoneal
drainage at earlier times would limit drug exposure.
We also compared our etoposide data with that obtained
in our previous pharmacokinetic study of cisplatin and
etoposide administered intraperitoneally (Zimm et al., 1987).
The dose of etoposide evaluated was 350 mg m-2 in both
studies. Due to differences in variances only the clearance
and peak concentration in the peritoneal cavity could be
compared (simultaneous F tests of the hypothesis of equal
variances, data analysis not shown). The present study yields
a longer half life (5.3 ± 1.4 h vs 3.1 ± 0.2 h) and a higher
peak concentration (302.2 ± 27.3,ug ml' vs 189 ± 2.2 tLg
ml-'). A similar problem of differences in variances limited
comparison ofplasma values to half life, AUC peak concent-
ration and time of peak concentration. The present half life
of 1.3 ± 0.4 was significantly shorter than the 5.8 ± 0.6
obtained in the previous study while no difference was noted
in the AUC (314.5 ± 50.3 g-h ml' vs 356 ± 14 ggh ml-')
peak concentration (27.67 ± 3.6lg ml- ' vs 32 ± 3.1 fig ml-')
or time of peak concentration (3.3 ± 0.4 h vs 3.7 ± 0.2 h).
The slow peritoneal clearance in the present study is consis-
tent with the higher peak peritoneal concentration achieved,
however, despite a significant decrease in plasma half life
there was no affect on the AUC or peak concentration.
Recent data from Los et al. (1990) has called into question
the rationale of using carboplation via the intraperitoneal
route. Their data suggest that carboplatin is far less efficient
than cisplatin in penetrating tumours. In fact, ten times more
carboplatin was required to achieve tumour content of
platinum equal to that ofcisplatin in their rat model. Despite
this information, in this trial, clinically meaningful responses
were observed in patients with ovarian cancer. The overall
response rate was 27% in ovarian cancer patients.
Similarly, Markman et al. (1992) have recently reported an
overall response rate of 38% in patients with ovarian cancer
treated with these same agents IP. In this study, 44% of
patients with disease 0.5 cm responded with eight (32%)
achieving a complete response. In our own study, three of the
four patients with ovarian cancer that responded to this788 E.F. McCLAY et al.
combination had previously received systemic cisplatin. One
of the four patients had also received high doses of cisplatin
(1200 mg m-2 total dose) administered intraperitoneally. This
clinical response suggests activity of intraperitoneal carbop-
latin and etoposide in patients with ovarian cancer who have
previously failed or relapsed from cisplatin containing
regimens and argues strongly for continued evaluation of this
combination in combination with colony stimulating factors
to allow further dose escalation.
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